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Abstract
Background: Evidence for extra-motor involvement in non-demented patients with amyotrophic
lateral sclerosis (ALS) has been provided by multiple studies, in particular neuropathological studies
have demonstrated neuronal loss in the amygdala. The aim of this study was to investigate possible
alterations of amygdala volumes in vivo.
Methods:  Twenty-two moderately disabled patients with definite ALS without cognitive or
behavioural deficits and 22 age-matched healthy controls were included. Amygdala and total brain
volumes were measured by region-of-interest-based volumetry in 3-D MRI.
Results: A trend was observed with reduced amygdala size in the ALS group, since mean absolute
and brain size-corrected amygdala volumes were 6.9% and 7.6% lower in the patient group
compared to those in normal controls (P = 0.086 and P = 0.110), respectively.
Conclusion: Volumetrically identifiable alterations of the amygdala can be mapped in vivo and may
be associated with psychopathological findings in later stages of ALS.
Background
Amyotrophic lateral sclerosis (ALS) is characterised by a
progredient degeneration of upper and lower motor neu-
rons, but there is growing evidence for extra-motor
involvement in non-demented patients with ALS that has
been provided in neuropathological, neurophysiological,
electrophysiological, and neuroimaging studies [1-4]. Not
only is the association of motor neuron diseases (MND)
with dementia of frontotemporal type well-established,
but also the finding of frontotemporal cortex atrophy has
been reported at autopsy of patients with the clinical diag-
nosis of MND without clinical signs of dementia [4].
However, neuropathological extra-motor alterations are
not limited to neocortical regions. Ubiquitin immunore-
active inclusions, as they are observed in lower motoneu-
rons in ALS [5], were also found in neurons of the
amygdala, in particular the baso-lateral aspect, in more
than 30% of cases out of a group of non-demented MND
patients [6]. Moreover, animal experiments in transgenic
mice of a functionally altered glutamate AMPA receptor
subunit (GluR-B(N)) which can result in a phenotype
characterized by a pattern of neurodegeneration and pro-
gressive motor decline resembling MND in humans,
exhibited a selective loss of neurons in the amygdala [7].
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The amygdala is known to be an important element of the
limbic system, so its involvement may be an important
factor for behavioural changes or particularly for altered
emotional responses in ALS without dementia, as they
have been demonstrated in a previous study [8].
In vivo investigations of pathological changes using high-
resolution magnetic resonance imaging (MRI) raise the
possibility of analysing the topography of volume altera-
tions. So far, there are no studies specifically investigating
amygdala pathology in MND using modern MRI tech-
niques. In this MRI-based volumetric study, we tested the
hypothesis that there is amygdala volume loss in patients
with ALS by a comparison with healthy subjects.
Methods
Patients and controls
The study was approved by the local ethics committee
(Ethics Committee of the University of Ulm), and all
patients gave their written informed consent. Twenty-two
patients with a clinical diagnosis of ALS according to the
revised El Escorial criteria for the diagnosis of ALS [9] were
included in the study (mean age 58 ± 9 years; 19 men, 3
women). The MRI data of the same patients and the con-
trols had been previously analysed by automated tech-
niques (voxel-based morphometry) in which no volume
alterations of the amygdala were observed in a whole
brain study at group level [10]. All patients had clinical
evidence of upper motor neuron degeneration as well as
clinical and electrophysiological evidence for lower motor
neuron involvement in at least three regions, as shown by
independent investigations by two experienced neurolo-
gists at the time of scanning. Nineteen patients had limb
onset, three had bulbar onset. The mean time between
onset of motor symptoms (as assessed by patients' self-
reports) and MRI scanning was 2 years. The ALS Func-
tional Rating Scale [11] ranged from 20 to 40 (median
30). A neuropsychological test battery was performed
including tests for frontal functions (Regensburg Fluency
Test for verbal fluency or 5-Point Fluency Test for design
fluency), Symbol Digit Modalities Test, Wisconsin Card
Sorting Test (PC version), Doors Test, and Beck's Depres-
sion Inventory (BDI). Here, design fluency, planning and
conceptual formation, attention, and visual memory were
unimpaired in all patients, verbal fluency was normal in
all but two patients. The patients scored a mean of 7
(range 4–16) in BDI, only two patients fulfilled the crite-
ria of mild depression; thus, none of the patients met the
cutoff for moderate depression of 18. There were no
behavioural abnormalities in all patients.
A control cohort was set up by acquiring MRI data from an
age-matched group of 22 healthy subjects (mean age 59 ±
11 years; 17 men, 5 women) by use of the same scanning
protocol. All volunteers were neurologically and neu-
ropsychologically normal (as shown by the use of the
same test battery), none had any history of neurological or
psychiatric disease or other medical conditions.
Data acquisition and processing
High-resolution MRI was acquired in all subjects on the
same 1.5 Tesla clinical scanner with a standard quadrature
headcoil (Siemens, Erlangen, Germany). Three-dimen-
sional data sets of the whole brain were collected using a
T1 weighted magnetisation prepared rapid acquisition
gradient echo (MP-RAGE) sequence, consisting of 160 to
180 sagittal partitions depending on head size. The acqui-
sition parameters were as follows, repetition time 9.7 ms;
echo time, 3.93 ms; flip angle, 15°; matrix, 256 × 256
mm2; field of view, 250 mm.
All MRI data were processed by use of the interactive soft-
ware program MRreg  (L. Lemieux, Epilepsy Imaging
Group, Dept. of Clinical and Experimental Epilepsy, Insti-
tute of Neurology, UCL, London, UK [12]) which enables
volumetric measurements by manual delineation of spe-
cific intracerebral structures. For assessment of the total
brain volume, the brain structures were manually out-
lined in every tenth slice at a 2 times magnification using
the semi-automatic threshold and region growing tool to
delineate cerebrum, cerebellum, upper brainstem accord-
ing to [13]. The resulting voxel number was multiplied by
the voxel volume to give the in-slice brain volume (cm3),
and the total brain volume was then obtained by multipli-
cation of the sum of the in-slice volumes by 10. For out-
lining the amygdala, the images were zoomed to a 4 times
magnification. The volumes were then measured by delin-
eating the amygdala boundaries for each hemisphere sep-
arately, following the established protocol described by
Watson et al. [14]. The in-slice volume (i.e., the volume of
the delineated amygdala in each slice) was calculated by
multiplying the number of voxels contained within each
trace by the voxel volume and dividing this value by the
magnification factor 4. The sum of all in-slice volumes
resulted in the total volume of each amygdala. Represent-
ative slices showing total brain and amygdala delineation
are given in Figure 1. For calculation of the relative amy-
gdala size, the amygdala volumes were divided by the
total brain volume of the subject, providing the propor-
tion amygdala/total brain and thus a correction for indi-
vidual brain size [15].
The rater was trained in volume-of-interest-based analysis
of MRI and was blinded to the subject grouping. Intrarater
reliability was tested by repeated measurements of a sub-
set of 10 subjects.
Patient and control groups were compared using the t-test
within the Statistical Package for the Social Sciences soft-
ware (SPSS, Version 12.0, Chicago, IL, USA). A two-sidedBMC Neurology 2006, 6:48 http://www.biomedcentral.com/1471-2377/6/48
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level of significance of 0.05 was defined. The intrarater
reliability was assessed by four different methods: (i) the
ratio of measured standard deviations to average amy-
gdala volumes (coefficient of variation), (ii) the coeffi-
cient of repeatability, Cr [16], (iii) an intraclass correlation
coefficient, and (iv) the similarity index (SI) in order to
compute measures of overlap of the ROIs according to
Heckemann et al. [17,18].
Results
Volumetric measurements
Table 1 summarises the volumetric findings. Both for left
and for right amygdala, the patients' mean volumes were
lower than the controls', with no significant asymmetry
effect (left vs. right amygdala volumes, p = 0.212 in
patients and p = 0.335 in controls). The comparison of
uncorrected right-sided amygdala volumes between
patients and controls was statistically significant, but uni-
lateral findings or amygdalar asymmetry was not included
in our hypothesis-driven approach. The total brain vol-
umes were 1,127.7 ± 140.1 cm3 in patients and 1,135.6 ±
167.7 cm3 in controls (p = 0.440). The total amygdala vol-
umes, both as the absolute value and corrected for brain
size, were lower in the ALS patients. However, this finding
has to be judged as a trend since it failed to reach statistical
significance (p = 0.086 for absolute and p = 0.110 for rel-
ative volumes, respectively). Corrected amygdala volumes
plotted against total brain volumes are shown in Figure 2.
Reliability data
For intrarater reliability, the coefficient of variation was
8.5%. The coefficient of repeatability (Cr) was 224 mm3,
i.e. 14% of the overall mean, and the intraclass correlation
coefficient was 0.65. All these values corresponded well to
what has been reported in the literature [19]. The mean SI
was 0.793 ± 0.038 (range 0.736–0.849) for the right amy-
gdala and 0.783 ± 0.029 (range 0.723–0.843) for the left
amygdala. These values also corresponded well to previ-
ous studies [17].
Discussion
The volumetric 3-D MRI-based measurements of amy-
gdala demonstrated a trend for volume reduction in
patients with clinically definite ALS, i.e. a mean decrease
by 6.9% in absolute and 7.6% in corrected values. These
data are in general accordance with autopsy studies which
describe intraneuronal inclusion bodies and marked glio-
sis in the amygdala of ALS patients [6], although it has to
be held that these histological changes might not influ-
ence volumes per se. Another reason for the apparent dis-
crepancy between the marked amygdala alterations in
neuropathological studies and the non-significant find-
ings in MRI-based studies might be that the latter includ-
ing the present one were performed in patients who were
moderately disabled and that amygdala changes might be
more pronounced in the later stages. The neuropatholog-
ical findings seem to be more common in ALS patients
Examples of single 3-D MRI slices, showing delineation of in-slice volumes of total brain (left) and amygdala (right) [green] and  the defined superior limit according to Watson et al. [14] [white] within MRreg Figure 1
Examples of single 3-D MRI slices, showing delineation of in-slice volumes of total brain (left) and amygdala (right) [green] and 
the defined superior limit according to Watson et al. [14] [white] within MRreg.BMC Neurology 2006, 6:48 http://www.biomedcentral.com/1471-2377/6/48
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with dementia [2], but they are not limited to these cases
and are found in non-demented ALS patients as well [6].
The lower volumes in ALS are obviously a subtle finding
in in vivo studies which was only detected when amygdala
volumes were specifically addressed – in contrast, there
were no amygdala changes found in previous whole
brain-based investigations in ALS using statistical compar-
isons of 3-D MRI data (voxel-based morphometry), nei-
ther in non-demented ALS patients [10] nor in patients
suffering from ALS/frontotemporal lobar degeneration
complex [20]. The trend for lower amygdala volumes is
the more remarkable since there was no global atrophy of
the ALS patients' brains found here (i.e., the total brain
volumes did not differ from controls), opposite to previ-
ously used automated techniques [10]. These discrepant
findings might be explained by the basic methodological
differences in global atrophy assessment between the two
studies. In the present study, a volume-of-based approach
was used on 3-D MRI data in native space to determine
total brain volumes, for the purpose of correcting absolute
amygdala volumes for global brain atrophy in a ratio of
absolute volumes. In the previous study [10], brain paren-
chymal fractions (BPF) were investigated, i.e. size-normal-
ised proportions of grey matter and white matter volumes
to total intracranial volumes, calculated after pre-process-
ing steps including statistical parametric mapping (SPM)-
based spatial normalisation to standard space and auto-
matic segmentation. Obviously the manual ROI delinea-
tion and automatic growing tool, performed in every
tenth slice, within MRreg on the one hand and the SPM-
based automatic processing of normalised data on the
other hand produced different results with respect to the
statistical significance of the comparison of ALS patients
and controls.
Table 1: Synopsis of volumetric findings in ALS patients and controls (mean values ± SD).
right amygdala volume [cm3] left amygdala volume [cm3] total amygdala volume [cm3] proportion of amydala to total brain volume [× 10-3]
patients 1.487 ± 0.262 1.526 ± 0.312 3.014 ± 0.534 2.69 ± 0.609
controls 1.628 ± 0.258 1.610 ± 0.288 3.239 ± 0.512 2.91 ± 0.488
t-test P = 0.043 P = 0.186 P = 0.086 P = 0.110
Relative amygdala volumes plotted against total brain volumes in ALS patients and controls Figure 2
Relative amygdala volumes plotted against total brain volumes in ALS patients and controls.BMC Neurology 2006, 6:48 http://www.biomedcentral.com/1471-2377/6/48
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The functional impact of the subtle structural amygdala
abnormalities is hard to assess. The amygdala is believed
to be important among other functions for evaluation of
the emotional valence of stimuli in the early phases of
sensory processing (assigning emotional significance to
specific sensory input [21]), linkage of perceptual repre-
sentation to emotional memories and regulation of auto-
nomic responses [22]. In humans, the amygdala appears
to be especially important for processing of emotional
information in a social context [23]. Affection and emo-
tional processing in ALS is poorly understood beyond the
general agreement that ALS patients do not develop a
depressive disorder despite the severe impact of the dis-
ease on their lives. It has been demonstrated that emo-
tional responses of ALS patients tend to be altered towards
positive valence [8], and it seems a plausible concept that
alterations of the amygdala might be involved in this
process.
Whether the volume reduction implies per se a loss of
function of the amygdala or is just the morphological cor-
relate of a generally altered function, remains unresolved.
According to a PET study, a group of non-demented MND
patients had a reduced regional cerebral blood flow in
limbo-thalamic areas [24], indicative of functional
decrease. With respect to cognitive abilities, the division
of human behaviour into emotion and cognition is not as
clear as previously suggested, and the finding that brain
regions linked to executive function and working memory
are correlated with amygdala response suggests one path-
way by which complex cognitive manipulations of stimuli
might influence the neural circuitry of emotion, so for
instance an indirect communication between frontal cor-
tical areas and amygdala exists [25]. The involvement of
amygdala volume decreases in dementia, even as a predic-
tive factor, has been demonstrated, however, only for
Alzheimer disease yet [26], but might be part of the ALS/
dementia complex as well.
Conclusion
In summary, a trend for volume alterations of the amy-
gdala in ALS could be observed in vivo by use of MRI vol-
umetry. Additional investigations in later stage patients
and patients with dementia and/or distinctive behav-
ioural deficits promise further insights in the role of lim-
bic system involvement within the multi-system
degeneration process of MND.
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